This narrative review explores current insights into the potential use of medicinal cannabis-related products as an emerging therapy for opioid use disorder in the landscape of increasing knowledge about medicinal cannabis-based products, commercialisation and global legalisation. Preclinical studies have provided preliminary insight into the putative neurobiological mechanisms that underpin the potential for medicinal cannabis to be considered a therapeutic in opioid use disorder and addiction. With the progressive legalisation of cannabis in many jurisdictions worldwide, contemporary research has highlighted further evidence that medicinal cannabis may have efficacy in reducing cravings and withdrawal effects, and therefore may be considered as an adjunct or standalone to current medications for opioid use disorder. Despite this potential, the landscape of research in this space draws from a large number of observational studies, with a paucity of rigorous randomised controlled trials to ascertain a true understanding of effect size and safety profile. With current challenges in implementation that arise from political and legal qualms about adopting medicinal cannabis on the background of associated social stigma, significant hurdles remain to be addressed by government, policy-makers, healthcare providers and researchers before medical cannabis can be introduced globally for the treatment of opioid use disorder.
Keywords: Cannabidiol; Cannabinoids; Cannabis; Medications for opioid use disorder; Medicinal cannabis; Opioid replacement therapy; Opioid use disorder; THC; Tetrahydrocannabinol.
The aim of this review was to synthesise current evidence to understand how medicinal cannabis products may be able to tackle the signs, symptoms and outcomes related to opioid dependence. At the present time, opioid dependence is associated with a significant burden of disease and death in the community. Current treatment for opioid dependence includes supplying controlled-release opioids in a regulated (and often observed) manner in the community. However, despite the implementation of this strategy, the outcomes related to opioid use and dependence remain relatively unchanged, indicating that the current gold standard treatment is not as effective as it should be. Following the legalisation and commercialisation of medicinal cannabis, there has been increased research into the ways these products can be leveraged for different conditions and indications, including in opioid dependence. Given this context, in this narrative we explore this preliminary evidence and evaluate the steps required in further research and policy changes before more widespread implementation of medical cannabis can be considered.
© 2024. The Author(s).